Hugo Cabrera
Hugo Cabrera is a biotechnology entrepreneur specializing in Advanced Therapy Medicinal Products (ATMPs) such as cell therapy, gene therapy, and tissue engineering.
He has licensed intellectual property from the São Paulo Federal University (UNIFESP) for the production of autologous serum eye drops and is in the final stages of technology transfer for a product release in Q4-2020.
Cabrera is currently developing third-generation autologous chondrocyte implantation (ACI) for knee cartilage repair, with Marketing Authorization (MA) expected in Q1-2021.
He is leading a strategic collaboration to introduce TAPCells®, a dendritic cell (DC) vaccine for melanoma and prostate cancer, to the Brazilian market.
Hugo has a diverse educational background, including studies in Administration, Strategic Management, Marketing Management, Business Management, and regenerative medicine business at prestigious institutions such as Harvard and Richmond University.
In his professional journey, Cabrera has held various roles such as Director of Business Development at Techlife Biotech, Founder of HMCell, Brazil Country Manager at Cellus Medicina Regenerativa S.A., Key Account Manager at Tyco Integrated Security, among others.
He has experience in strategy, marketing consulting, sales development, trade marketing, supply chain management, and retail operations in reputable organizations.
Additionally, Hugo Cabrera has volunteered as an English teacher and possesses a well-rounded skill set in negotiation, business development, and entrepreneurship.
